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Lung tumour subtyping, particularly the distinction between ade-
nocarcinoma (AdC) and squamous cell carcinoma (SqCC), is a crit-
ical diagnostic requirement. In this work, the metabolic signatures 
of lung carcinomas were investigated through 1H NMR metabo-
lomics, with a view to provide additional criteria for improved 
diagnosis and treatment planning. High Resolution Magic Angle 
Spinning Nuclear Magnetic Resonance (NMR) spectroscopy was 
used to analyse matched tumour and adjacent control tissues from 
56 patients undergoing surgical excision of primary lung carcino-
mas. Multivariate modeling allowed tumour and control tissues 
to be discriminated with high accuracy (97% classification rate), 
mainly due to significant differences in the levels of 13 metabolites. 
Notably, the magnitude of those differences were clearly distinct for 
AdC and SqCC: major alterations in AdC were related to phospho-
lipid metabolism (increased phosphocholine, glycerophosphocho-
line and phosphoethanolamine, together with decreased acetate) 
and protein catabolism (increased peptide moieties), whereas SqCC 
had stronger glycolytic and glutaminolytic profiles (negatively cor-
related variations in glucose and lactate and positively correlated 
increases in glutamate and alanine). Other tumour metabolic fea-
tures were increased creatine, glutathione, taurine and uridine 
nucleotides, the first two being especially prominent in SqCC and 
the latter in AdC. Furthermore, multivariate analysis of AdC and 
SqCC profiles allowed their discrimination with a 94% classifica-
tion rate, thus showing great potential for aiding lung tumours 
subtyping. Overall, this study has provided new, clear evidence of 
distinct metabolic signatures for lung AdC and SqCC, which can 
potentially impact on diagnosis and provide important leads for 
future research on novel therapeutic targets or imaging tracers.
Introduction
Lung cancer is a complex, heterogeneous disease with high inci-
dence and mortality worldwide, being responsible for 22.5 and 
13.8% of cancer-related deaths in men and women, respectively (1). 
Besides prevention, namely through smoking cessation, one of the 
greatest hopes to improve lung cancer management relies on person-
alized medicine, i.e. the selection of the safest and most efficacious 
treatment for each patient, based on the specific tumour pathologi-
cal characteristics (2). According to the World Health Organization 
(WHO), malignant epithelial lung tumours are classified into seven 
major categories, the most prevalent histological types being adeno-
carcinoma (AdC) and squamous cell carcinoma (SqCC [3]). Several 
clinical trials have demonstrated differing efficacy and/or toxicity of 
particular treatments depending on tumour histological type, thus 
making accurate subtyping of lung tumours, particularly the distinc-
tion between AdC and SqCC, a mandatory diagnostic requirement 
(4). Tumour subtyping is normally performed by morphological 
assessment through light microscopy, whereas in cases of poorly 
differentiated tumours or small biopsy specimens, immunohisto-
chemical markers are needed to achieve reliable subtyping (5).
Metabolic reprogramming of tumour cells to support continuous 
growth and proliferation is recognized as an emergent hallmark in can-
cer development (6). Indeed, there is cumulative evidence that many 
solid tumours show altered metabolic pathways, such as enhanced 
glucose uptake and glycolytic activity, increased de novo biosynthesis 
of nucleotides, increased glutaminolysis or a shift in citrate metabo-
lism from oxidation to lipogenesis (7,8). Therefore, new insights into 
disease molecular aetiology, diagnostic markers or potential thera-
peutic targets will probably arise from the in-depth study of tumour 
cell metabolism. Metabolomic profiling of tumour tissues by 1H High 
Resolution Magic Angle Spinning (HRMAS) nuclear magnetic reso-
nance (NMR) spectroscopy offers a direct window to cancer altered 
metabolism, as tissue metabolite levels closely reflect the metabolic 
activity of tumour cells and their microenvironment. This approach 
has enabled general and specific metabolic markers of malignancy to 
be proposed for different cancer types and has great potential to assist 
in the interpretation of in vivo MRS data (9).
The metabolic features of lung carcinomas have been explored 
before by our group and others, either by direct HRMAS NMR spec-
troscopy (10–12) or by analysis of tissue extracts using NMR (13,14) 
or Mass Spectrometry (MS) methods (15,16). Although involving 
small numbers of patients (from 7 to 24), the previous studies have 
provided preliminary evidence for abnormal metabolism in malig-
nant tissue, hence stimulating the more thorough examination of lung 
tumour metabolic signatures and their relation to histological and 
clinical parameters. This work represents the first global metabolomic 
study of a considerably larger sample set (over 100 tissue samples 
from 56 lung cancer patients), where direct tissue analysis by 1H 
HRMAS NMR spectroscopy has been combined with multivariate 
modeling and validation procedures to ensure the robustness of find-
ings. With this approach, besides characterizing the general metabolic 
features of malignant lung tumours, we aim to investigate the differ-
ences in the metabolic behaviour of adenocarcinoma and squamous 
cell carcinoma, as these differences may provide additional criteria 
for complementing diagnosis and improving clinical decisions.
Materials and methods
Subjects
In total, 56 subjects diagnosed with primary lung cancer at surgical stage 
(40M/16F, 62 ± 10 average age) were included in this study, following 
informed consent and approval of the study protocol by the Ethics Committee 
of the University Hospitals of Coimbra. Supplementary Table  1, available 
at Carcinogenesis online, shows the information available for each subject. 
Final diagnosis was established after histopathological examination of surgical 
specimens, the tumours having been classified as 19 AdCs, 19 SqCCs, 6 sar-
comatoid carcinomas, 4 large cell carcinomas, 2 adenosquamous carcinomas, 
4 carcinoid tumours and 2 small cell carcinomas, according to the 2004 WHO 
Classification of Tumours (3). Based on the TNM staging system, most cases 
were classified as stage I (n 30) and stage II (n 18) and a few cases were of 
Abbreviations: AdC, adenocarcinoma; GSH, glutathione; GPC, glycerophos-
phocholine; HRMAS, high resolution magic angle spinning; MCCV, Monte Carlo 
cross validation; NMR, nuclear magnetic resonance; PC, phosphocholine; PE, 
phosphoethanolamine; PLS-DA, Partial Least Squares Discriminant Analysis; 
ROC, receiver operating characteristic; SqCC, squamous cell carcinoma; UDP/
UTP, uridine di/triphosphate; VIP, variable importance to the projection.
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stage III (n 6). In all cases, the surrounding parenchyma presented histological 
characteristics of ‘smoking lung’, mostly emphysema and bronchiolitis. The 
smoking history of the patients was not available.
Tissue sampling and preparation
Lung tumour and non-involved adjacent tissue (control) samples were retrieved 
from surgical specimens within a maximum of 30 min after surgery, immedi-
ately snap-frozen in liquid nitrogen and stored at −80°C until NMR analysis. 
The percentages of tumour cells and of necrotic tissue were determined by 
microscopic observation of mirror sections of samples collected for NMR and 
are presented in Supplementary Table 1, available at Carcinogenesis online. At 
the time of analysis, the frozen tissues were washed with a few drops of D2O 
saline (0.9%) to remove excess blood, and ca. 40 mg of thawed cold tissue was 
packed into 50 µl HRMAS rotors, containing 10 μl of D2O saline with 0.25% 
3-(trimethylsilyl) propionate sodium salt (TSP)-d4 to provide a signal for lock 
(D2O) and for shimming (TSP).
NMR measurements
NMR spectra were acquired on a Bruker Avance DRX-500 spectrometer oper-
ating at 500.13 MHz for 1H observation, at 277 K, using a 4 mm HRMAS probe, 
in which the rotor containing the sample was spun at 4 kHz. Standard 1D 1H 
spectra with water presaturation (pulse program ‘noesypr1d’, Bruker library) 
were acquired with a 6510 Hz spectral width, 32 K data points, a 4 s relaxa-
tion delay (d1), 100 ms mixing time (d8) and 256 scans. A T2-edited spectrum 
(pulse program ‘cpmgpr’) and a diffusion-edited spectrum (pulse program 
‘ledbpgp2s1dpr’) were also recorded for each sample, as described previously 
(10). All 1D spectra were processed with a line broadening of 0.3 (standard and 
T2-edited) or 0.5 Hz (diffusion-edited), zero filling to 64 K data points, manual 
phasing and baseline correction. The chemical shifts were referenced internally 
to the alanine signal at δ 1.48 ppm. Spectral assignment was based on 2D total 
correlation spectroscopy (TOCSY) and heteronuclear single quantum coher-
ence (HSQC) spectra (10), consultation of spectral databases, namely Bruker 
Biorefcode database and the human metabolome database (HMDB [17]) and 
further supported by statistical total correlation spectroscopy (STOCSY [18]).
Multivariate analysis and spectral integration
A total of 115 spectra corresponding to tumour and matched control tissues 
from 56 lung cancer patients (112 + 3 extra samples) were considered for 
multivariate analysis. Spectra were aligned using recursive segment-wise peak 
alignment (19) to minimize chemical shift variations, and normalized by prob-
abilistic quotient normalization (PQN [20]), using the median of the control tis-
sue spectra as reference, to account for dilution-independent effects on spectral 
area. Scaling to unit variance (UV) was then performed to highlight changes in 
low abundance metabolites. Data matrices were built in Amix-viewer (version 
3.9.14, BrukerBiospin, Rheinstetten, Germany) using all intensity values in 
the δ 0.25–8.80 region (excluding the subregions containing suppressed water 
and contaminant signals from ethanol and polyethyleneglycol) or, in some 
instances, subsets of signal integrals or selected variables. Variable selection 
was based on the intersection method described by Diaz et  al. (21), which 
accounted for the variable importance to the projection (VIP greater than 1) 
as well as VIP standard errors and b-coefficients. Principal component analy-
sis, used to detect intrinsic grouping and/or outliers within the data set, was 
followed by Partial Least Squares Discriminant Analysis (PLS-DA) to maxi-
mize class discrimination (SIMCA-P 11.5, Umetrics, Umeå, Sweden). Model 
robustness was assessed by Monte Carlo Cross Validation (MCCV [22]) with 
500 iterations and permutation testing (class membership randomly assigned). 
The distribution of Q2 values (expressing the cross-validated prediction power) 
and the receiver operating characteristic (ROC) maps, representing the true 
positive rate (TPR or sensitivity) as a function of the false positive rate (FPR 
or 1-specificity), were recovered from MCCV applied to both original and 
permuted models. PLS1 regression was employed to assess the relationship 
between tissue metabolic profiles and different clinical and histological param-
eters (e.g. age of subjects, % of tumour cells, % necrosis).
To evaluate metabolite quantitative variations, selected signals in the 
standard 1D spectra were deconvoluted and integrated using Amix-Viewer 
(version 3.9.14, BrukerBiospin), as described previously (10), and normal-
ized by the PQN quotient of each spectrum. Statistically significant differ-
ences in integral values between the groups compared were assessed using 
the t-test or the non-parametric analogue Wilcoxon rank-sum test with 
continuity correction. Statistical significance was assessed by Bonferroni-
corrected P values (confidence level 95%). Moreover, effect sizes and cor-
responding confidence intervals were estimated to evaluate the magnitude of 
the differences, as described in Berben et al. (23). Additionally, Spearman 
correlation analysis was employed to evaluate the correlations within NMR 
variables and between these and some histological parameters, using a corre-
lation coefficient cut-off of |r| > 0.7 and correlation significance of P < 0.004 
(Bonferroni-corrected).
Results
General metabolic profile of lung tumours
Figure 1 shows the average spectral profiles of pulmonary control 
tissue and of the different lung tumour types analysed. Although 
there were several differences amongst the tumour profiles, which 
will be later addressed, some features (e.g. depleted glucose and 
increased lactate and phosphocholine) appeared to be common 
changes in relation to control tissue. Therefore, our first approach 
consisted of applying multivariate analysis to assess the discrimi-
nation between all tumours and control tissues, based on general 
metabolic features.
The resulting PLS-DA model, applied to standard 1D spectra, 
showed high explained variance and predictive power, the two tissue 
classes being well-separated along LV1 (Figure 2A). The robustness 
of this discrimination was then verified by MCCV and permuta-
tion testing, with prediction results being plotted in the ROC space 
(Figure 2B). While the original model (true classes assigned) showed 
96.1% sensitivity, 97.8% specificity and an overall classification 
rate of 96.9% (Supplementary Table  2, available at Carcinogenesis 
online), random permutation of class  membership resulted in a 
decrease of these parameters to values of no discrimination (approxi-
mately 50%). Moreover, the Q2 values obtained for the original model 
showed a high median (0.83) and a distribution clearly distinct from 
that obtained for permutations (Figure 2C), therefore confirming the 
predictive power of the original model. PLS-DA and MCCV were 
also applied to T2-edited and diffusion-edited spectra (Supplementary 
Figure 1, available at Carcinogenesis online). However, as shown by 
the resulting statistical parameters (Supplementary Table 3, available 
at Carcinogenesis online), the model built with the standard 1D spec-
tra was found to be the most robust (higher predictive power, sensi-
tivity and specificity); hence, further data analysis was based on the 
standard 1D experiment.
The thorough inspection of PLS-DA LV1 loading weights coloured 
as a function of VIP (Figure 2D) allowed the main compounds con-
tributing to tissue discrimination to be identified. Lactate, alanine, 
glutamate, reduced glutathione (GSH), creatine, taurine, phospho-
choline (PC), glycerophosphocholine (GPC), phosphoethanolamine 
(PE), uridine di/triphosphate (UDP/UTP) and peptide moieties (with 
negative loadings) were increased in tumours, whereas acetate and 
glucose (positive loadings) were decreased. Indeed, the integrals of 
all these metabolite signals showed statistically significant differences 
(P  <  0.004, Bonferroni-corrected) and absolute effect sizes greater 
than 0.5, thus confirming their importance in the discrimination 
between tumour and control tissues. The percentages of variation for 
each discriminant metabolite are presented in Table I (left) and cor-
responding boxplot representations can be found in Supplementary 
Figure  2, available at Carcinogenesis online. Further confirmation 
of the discriminatory power of this set of metabolites was achieved 
by PLS-DA of their integrals, as model robustness and accuracy was 
maintained (Supplementary Table  2 and Supplementary Figure  3, 
available at Carcinogenesis online).
As the amount of tumour cells on mirror sections of NMR-analysed 
samples was found to vary between 5 and 99% (Supplementary 
Table 1, available at Carcinogenesis online), median and mode val-
ues being 50 and 90%, respectively; the possible influence of such 
variability on tumour metabolic composition was addressed by PLS1 
regression, considering either the full spectral profile or the set of 
13 discriminant metabolites. The resulting Q2 values were very low 
(about 0.1 in both cases), thus indicating that the metabolic profiles 
of tumour tissues were not strongly determined by the varying pro-
portions of stromal and tumour cells on each sample. The possible 
correlation between the NMR spectral profiles and the amount of 
necrotic tissue (Supplementary Table 1, available at Carcinogenesis 
online) were also investigated through PLS1 regression. The resulting 
model (n 53)  showed a reasonable predictive power (Q2 0.48 for 2 
latent variables), with less necrotic samples located in negative LV1 
and samples with higher % necrosis distributed towards positive LV1 
(Supplementary Figure 4A, available at Carcinogenesis online). The 
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corresponding VIP-coloured loadings (Supplementary Figure  4B, 
available at Carcinogenesis online) indicated that higher lipid lev-
els characterized highly necrotic samples, which was confirmed by 
the significant correlations found between lipid signal areas and % 
necrosis.
Finally, the impact of stage on the tumour signature has been 
addressed by building separate PLS-DA models for each stage (I: 29 
pairs, II: 19 pairs, III: 6 pairs). While the stage III model couldn’t be 
properly validated, most probably due to the low number of samples 
available, the classification rates obtained for discriminating stage I or 
stage II tumours from their respective controls were similar to those 
achieved when considering the whole dataset (Supplementary Table 2, 
available at Carcinogenesis online). Moreover, inspection of the load-
ings profiles (not shown) revealed that the main discriminant features 
were the same for all stages, with the exception of taurine which did 
not appear important in the discrimination of stage III tumours from 
their controls. Concordantly, no valid discrimination between tumour 
tissues of different stages was obtained, thus indicating that, in the set 
of samples studied, stage did not have a major impact on the tumour 
metabolic profiles.
Metabolic behaviour of different tumour types: focus on AdC 
and SqCC
The differences between the tumour profiles shown in Figure  1 
suggest that there may be a relationship between tumour histomor-
phology and metabolic composition. For instance, carcinoids were 
characterized by very low lipid levels and high taurine and peptide 
abundance, whereas small cell carcinomas showed prominently high 
levels of creatine and myo-inositol together with absence of glucose. 
There were also several apparent differences in the relative levels of 
PC, GPC and glycogen. However, given the low sample numbers rep-
resenting most types (≤ 6 patients), only the profiles of AdC (n 19) and 
SqCC (n 19) were further examined in this study, with two main goals 
in mind: (i) to find out if these tumour types have distinct metabolic 
Fig. 1. Average standard 1D 1H HRMAS NMR spectra of lung control and tumour tissues of different histological types. Some apparent metabolite differences 
are indicated. FA, fatty acyl chains in lipids. *Ethanol contamination.
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behavior; (ii) to evaluate the potential of using NMR metabolomics as 
an adjunct tool in AdC versus SqCC differential classification.
To address the first goal, we have investigated the discrimination 
between each of these two tumour types and their respective con-
trol tissues. MCCV-validated PLS-DA models were obtained for 
both AdC and SqCC compared to controls, classification rates being 
87.8 and 97.7%, respectively (Supplementary Table  2, available at 
Carcinogenesis online). The corresponding scores scatter plots, ROC 
maps, Q2 distributions and loadings are shown in Supplementary 
Figure 5, available at Carcinogenesis online (A-D for AdC and E-H for 
SqCC). Notably, as confirmed by spectral integration, several metabo-
lites showed differing importance in the discrimination between either 
AdC or SqCC tumours and their respective control tissues. For instance, 
AdC showed higher increases in PC, GPC, UDP/UTP and peptides, 
whereas SqCC was characterized by higher increases of lactate, glu-
tamate, alanine, GSH and creatine, together with a more pronounced 
decrease of glucose (Table I, centre for AdC and right for SqCC).
Examination of dependencies between metabolite variations further 
complemented this analysis, the results being plotted as correlation 
heat maps colour-coded by the strength of Spearman correlation coef-
ficients (Figure 3). A striking observation was that the intermetabolite 
correlation pattern was clearly different between AdC and SqCC. In 
AdC, significant correlations (|r| > 0.7, P < 0.004, Bonferroni-corrected) 
involved mainly phospholipid-related metabolites (PC, GPC and PE), 
while the SqCC pattern was characterized by correlations involving lac-
tate, glucose, glutamate, alanine, GSH and creatine. A selected set of 
graphs showing the quantitative relationship between some metabolites 
found to be highly correlated in either AdC or SqCC can be found in 
Supplementary Figure 6, available at Carcinogenesis online.
For assessing the potential of metabolomics to discriminate 
between AdC and SqCC, multivariate analysis has been applied to 
their spectra, leaving out the control tissues. After excluding two 
clear outliers (AdC T13 and SqCC T37, characterized by very high 
lipids), the resulting PLS-DA model showed moderate accuracy and 
predictive power (classification rate 81.3% and median Q2 0.47) 
(Supplementary Table  2, available at Carcinogenesis online). This 
discrimination could, however, be significantly improved by applying 
the variable selection method described in the experimental section, 
allowing a model with 94.3% classification rate and median Q2 0.58 
to be built. The corresponding PLS-DA scores and MCCV validation 
results are shown in Figure  4. Furthermore, as the AdC and SqCC 
groups compared were unbalanced in terms of gender (AdC: 7M/11F; 
Fig. 2. Multivariate analysis of standard 1D 1H NMR spectra from lung control (n 57) and tumour (n 58) tissues (A) PLS-DA scores scatter plot (LV 2, R2X 0.27, 
R2Y 0.85, Q2 0.80), (B) ROC space and (C) Q2 histogram obtained from MCCV of the PLS-DA model (500 iterations), (D) PLS-DA LV1 loading weights (w) 
coloured as a function of VIP, where most important metabolites for group discrimination are indicated.
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SqCC: 16M/2F), possible gender-related bias has been assessed. The 
principal component analysis scores plot, where a trend for separa-
tion of tumour types was clear, showed no gender-related cluster-
ing (Supplementary Figure  7A and B, available at Carcinogenesis 
online). Moreover, when considering only adenocarcinoma samples 
(7M/11F), no valid discrimination could be achieved between males 
and females, as shown by the superimposed Q2 distributions and ROC 
spaces of true and permuted models (Supplementary Figure 7C and 
D, available at Carcinogenesis online). Therefore, gender could be 
excluded as an important confounding factor. In regard to age, the dif-
ference between groups was not statistically significant (median age 
64 and 63.5 for AdC and SqCC groups, respectively), thus reducing 
the possibility of any age-related bias. Moreover, the subjects’ age 
was found to have a negligible impact on the tumour tissue profile as 
expressed by the low Q2 values of PLS1 regression models built for 
each of the two major tumour types (not shown).
The metabolic features discriminating AdC and SqCC tumour tis-
sues were then inspected by integrating a number of signals within the 
variables selected. Those showing statistically significant differences 
(P < 0.002, Bonferroni-corrected) between AdC and SqCC are listed 
in Table II, along with the percentages of variation and effect sizes. 
Creatine and GSH were found to be relatively higher in SqCC, whereas 
PC, PE, myo-inositol and taurine were higher in AdC. The ability of 
this set of six signals to discriminate between AdC and SqCC was 
then further evaluated by PLS-DA of their integrals (Supplementary 
Figure  8, available at Carcinogenesis online). A  valid model could 
still be obtained although with lower classification rate (82.8%), thus 
showing the importance of considering a more comprehensive profile.
Discussion
The results hereby presented provide clear evidence of a strong 
metabolic signature for lung tumours, defined by a set of thirteen 
metabolites, which corroborates some typical features of cancer 
metabolism. Moreover, although sharing most of this malignancy 
signature, the major tumour types studied, adenocarcinoma (AdC) 
and squamous cell carcinoma (SqCC), were found to be character-
ized by important differences in their metabolic behaviour. While all 
tumours generally showed significantly depleted glucose together 
with increased lactate, this variation was much more pronounced in 
SqCC than in AdC, glucose and lactate levels showing a significant 
negative correlation in the former. These results highlight the depend-
ency of the known glycolytic phenotype of lung tumours, exploited 
in cancer diagnosis and staging through 18fluorodeoxyglucose (FDG) 
positron emission tomography (PET) imaging (24), on the histologi-
cal type. Concordantly, previous studies have shown that, compared 
to AdC, SqCC tumours were characterized by higher FDG uptake 
and increased overexpression of key membrane glucose transporters, 
namely GLUT1, necessary to support the high rate of glycolysis (25–
27). In addition to lactate, glutamate and alanine were also signifi-
cantly increased and positively correlated in SqCC tumours, whereas 
in AdC, glutamate registered a smaller increase and alanine did not 
differ significantly between tumour and control tissues. Glutamate 
may originate from hydrolysis of glutamine (glutaminolysis), which, 
in addition to glucose, is regarded as an important source of energy 
and intermediate building blocks for tumour cell growth (28,29). 
Subsequent transamination between glutamate and pyruvate, cata-
lysed by alanine transaminase, produces alanine and α-ketoglutarate, 
the latter entering the tricarboxylic acid cycle. Glutamate may also 
leave the glutaminolytic pathway and be excreted, as an effective way 
to excrete hydrogen, or to act as immunosuppressive in the protection 
of tumour cells (7). Therefore, our results suggest higher glutamino-
lytic activity for SqCC tumours than for AdC. Another important dif-
ference in the metabolic profiles of these histological types regarded 
the levels of reduced glutathione (GSH, γ-Glu-Cys-Gly) which 
were significantly increased in SqCC but not in AdC. GSH is a key 
Table I. Metabolites showing statistically significant differences (P < 0.004, Bonferroni-corrected) between lung tumours and control tissues, considering all 
samples (2nd column) or each of the main histological types (3rd and 4th columns)
Metabolite
(δ, multiplicity)a
All tumour types (56 pairs) Adenocarcinoma (19 pairs) Squamous cell (19 pairs)
% variation Effect size P value % variation Effect size P value % variation Effect size P value
Acetate
(δ 1.92, s)
−57.0 ± 17.2 −0.88 ± 0.39 3.3 × 10–6 −61.9 ± 22.2 −1.3 ± 0.70 1.3 × 10–4 n.s.
Alanine
(δ 1.48, d)
37.1 ± 5.3 1.1 ± 0.40 1.2 × 10–6 n.s. 46.9 ± 7.7 1.6 ± 0.73 1.6 × 10–4
Creatine
(δ 3.93, s)
63.9 ± 7.3 1.2 ± 0.40 1.2 × 10–8 28.2 ± 6.7 1.2 ± 0.69 6.4 × 10–4 126.4 ± 12.1 2.1 ± 0.79 3.8 × 10–6
Glucose
(δ 4.65, d)
−46.3 ± 6.8 −1.7 ± 0.43 7.9 × 10-10 −29.3 ± 10.8 −1.0 ± 0.68 2.0 × 10–3 −51.4 ± 11.4 −2.0 ± 0.77 3.8 × 10–6
Glutamate
(δ 2.35, m)
38.7 ± 3.8 1.6 ± 0.43 5.8 × 10-10 24.2 ± 5.8 1.2 ± 0.69 4.2 × 10–4 55.8 ± 6.1 2.3 ± 0.82 3.8 × 10–6
GPC
(δ 3.23, s)
118.4 ± 10.7 1.3 ± 0.41 5.0 × 10–8 115.2 ± 15.8 1.5 ± 0.72 2.1 × 10–4 n.s.
GSH
(δ 2.16, m)
42.8 ± 5.4 1.2 ± 0.40 2.3 × 10–9 n.s. 72.5 ± 9.9 1.7 ± 0.75 3.8 × 10–6
Lactate
(δ 4.12, q)
95.6 ± 5.1 2.4 ± 0.49 8.2 × 10–11 84.8 ± 7.4 2.6 ± 0.86 3.8 × 10–6 121.8 ± 9.1 2.7 ± 0.88 3.8 × 10–6
PC
(δ 3.22, s)
177.4 ± 18.7 0.95 ± 0.39 6.5 × 10–9 216.3 ± 21.5 1.6 ± 0.73 1.6 × 10–4 37.5 ± 11.6 0.88 ± 0.67 2.0 × 10–3
PE
(δ 3.98, m)
30.9 ± 4.5 1.1 ± 0.40 2.0 × 10–7 32.5 ± 5.8 1.6 ± 0.73 5.2 × 10–4 n.s.
Taurine
(δ 3.42, t)
56.0 ± 7.3 1.1 ± 0.40 6.6 × 10–7 n.s. n.s.
UDP/UTP
(δ 5.96, m)
255.2 ± 17.4 1.2 ± 0.40 6.3 × 10–9 422.2 ± 40.3 1.1 ± 0.68 8.0 × 10–4 243.7 ± 2 5.3 1.4 ± 0.71 1.3 × 10–4
Peptide
(δ 7.72, br)
17.8 ± 5.8 0.54 ± 0.38 2.2 × 10–4 28.0 ± 9.2 0.87 ± 0.67 2.0 × 10–3 n.s.
For each metabolite, the average percentage and coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and P values are 
shown, indicating, respectively, the magnitude and statistical significance of the differences between tumour and control tissues.
n.s. not significant.
as, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.
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component of the cellular defence system for detoxification of oxi-
dative stress-causing species or drugs. High intracellular GSH levels 
together with increased activity of GSH-related enzymes are a typi-
cal feature of several tumours (30), including lung tumours (31–33), 
and have been associated with chemoresistance and high metastatic 
potential (34). Regarding the GSH variation in lung tumours of dif-
ferent histology, our findings are consistent with an early report (35) 
but disagree with another study reporting higher GSH increase in AdC 
than in SqC compared to non-malignant adjacent tissue (33). It should 
however be noted that other patients characteristics, such as age and 
smoking habits, are expected to strongly influence the oxidative bur-
den, hence the tissue GSH levels. Therefore, data on the subjects 
smoking history, which is lacking in our study, would be necessary to 
further interpret the observed discrepancy and achieve solid conclu-
sions. Creatine was significantly increased in both tumour types but 
at much higher magnitude in SqCC than in AdC (126.4 versus 28.2% 
increase, respectively). Elevated creatine levels in tumour tissues have 
previously been related to altered energetic transfer processes (36,37) 
and may reflect decreased activity of creatine kinase (CK). Indeed, 
CK activity has been previously reported to be lower in both AdC and 
SqCC lung tumours, compared to normal adjacent tissues, although 
not showing a significant difference between tumour types (38).
In regard to phospholipid-related metabolites (PC, GPC and PE), 
the differences between tumour and control tissues were more marked 
in AdC than in SqCC. PC may arise from both anabolic and catabolic 
transformations of phophatidylcholine (PtdCho), the major cell mem-
brane phospholipid. A key enzyme involved in this cycle is choline 
kinase (ChoK), which phosphorylates choline to produce PC, as the 
first step in PtdCho synthesis. ChoK has been found overexpressed 
and highly active in lung tumours and cell lines (39,40), and has 
been proposed as a prognostic factor for early-stage lung cancer (40). 
Also, 11C-choline PET is being explored as an alternative to 18FDG-
PET in lung cancer staging, based on increased choline uptake and 
metabolism by rapidly proliferating tumour cells (41). On the other 
hand, phospholipid breakdown has also been linked to abnormal 
Fig. 4. Multivariate analysis of 1H NMR spectra from AdC (n 18) and SqCC (n 18) tissues, after exclusion of T13 and T37 (characterized by very high lipid 
levels) and application of variable selection: (A) PLS-DA scores scatter plot, (B) ROC space and (C) Q2 histogram obtained from MCCV of the PLS-DA model 
(500 iterations).
Fig. 3. Correlation heat maps colour-coded by the strength of Spearman 
correlation coefficients (r) between metabolites found to be important in 
tumour versus control discrimination: (A) AdC and (B) SqCC. Cut-off values 
of |r| > 0.7 and P < 0.004 (Bonferroni-corrected) have been used.
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metabolism in cancer and suggested to promote malignant trans-
formation via mitogenic signal transduction (9). As GPC is solely a 
product of PtdCho degradation, it is likely that the observed increases 
of PC and GPC, together with increased PE levels, reflect both ana-
bolic and catabolic processes, which our results suggest to be more 
relevant in AdC. Additionally, significantly decreased acetate levels in 
AdC (not observed in SqCC) may also relate to lipid metabolism as 
this metabolite can be converted to acetyl-CoA to feed de novo bio-
synthesis of lipids. Indeed, the shift from citrate oxidation to lipogen-
esis is another typical feature of cancer metabolism (42). However, 
although total lipids did show a (non-significant) trend to be higher 
in tumours, their levels seemed to be influenced by other factors like 
necrosis and did not prove determinant in the discrimination between 
malignant and non-malignant tissue. AdC tumour spectra were also 
characterized by increased contributions from peptide moieties, while 
no significant difference existed between SqCC and their respective 
controls. Concordantly, Wu et al. (43) have found elevated levels of 90 
dipeptides in lung AdC tissues (from nine patients) relatively to normal 
tissues. In another study (44), 17 dipeptides were found to be increased 
in cancer-associated fibroblasts (CAFs) isolated from lung tumours, 
compared to matched normal fibroblasts obtained from non-neoplas-
tic tissues. The authors postulated that the observed increase could 
relate to enhanced autophagy, a lysosome-related protein degradation 
mechanism, which has recently emerged as a key regulator of multi-
ple aspects of cancer biology (45,46). Finally, uracil nucleotides (UDP 
and/or UTP) were found to be significantly increased in tumours, espe-
cially in AdC. Given the important role of these molecules as extracel-
lular signalling molecules (47) and in cancer-related glycosylation of 
proteins and lipids (48), this is an interesting clue to further investigate 
their biological relevance in the context of lung cancer.
Regarding the differential classification of AdC and SqCC, the main 
metabolites highlighted as being significantly different between the 
two tumour types were creatine and GSH (higher in SqCC), together 
with PC, PE, myo-inositol and taurine (higher in AdC). Interestingly, 
the latter two metabolites, known to play a role in cellular osmopro-
tection, were important in AdC versus SqCC discrimination in spite of 
not being significantly different between each tumour type and their 
respective control tissues.
In summary, this work provided new, clear evidence that lung AdC 
and SqCC show distinct metabolic behaviour. Major alterations in 
AdC tumours regarded phospholipid metabolism and protein catab-
olism, whereas SqCC had a much stronger glycolytic and glutami-
nolytic profile. This difference could have important implications in 
the selective definition of the most appropriate targets for developing 
new anticancer therapies or imaging tracers in lung cancer research. 
Furthermore, NMR metabolomics has shown great potential for dis-
criminating between AdC and SqCC tissues, based on a set of selected 
variables, thus highlighting the valuable role of this approach in 
the subtyping of tumours. Future work will focus on the metabolic 
profiling of more challenging samples, with uncertain histomorphol-
ogy, with a view to compare the classification accuracy of metabolic 
markers with that of established immunohistochemical markers.
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